Multinational healthcare company Johnson & Johnson (NYSE: JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts’ consensus estimates.
Is now the time to buy JNJ?
Johnson & Johnson (JNJ) Q1 CY2025 Highlights:
- Revenue: $21.89 billion vs analyst estimates of $21.56 billion (2.4% year-on-year growth, 1.5% beat)
- Adjusted EPS: $2.77 vs analyst estimates of $2.58 (7.3% beat)
- Adjusted EBITDA: $9.16 billion vs analyst estimates of $8.39 billion (41.8% margin, 9.2% beat)
- The company slightly lifted its revenue guidance for the full year to $92 billion at the midpoint from $91.3 billion
- Management reiterated its full-year Adjusted EPS guidance of $10.60 at the midpoint
- Operating Margin: 28.3%, in line with the same quarter last year
- Free Cash Flow Margin: 43.2%, up from 13.3% in the same quarter last year
- Organic Revenue rose 3.3% year on year (5.2% in the same quarter last year)
- Market Capitalization: $380.2 billion
Johnson & Johnson’s latest quarter was shaped by ongoing growth in its innovative medicine and MedTech segments, as highlighted on the company’s earnings call. CEO Joaquin Duato cited 4.2% operational sales growth in innovative medicine, despite the negative impact from biosimilar competition for STELARA, and emphasized the company’s strong product launches and portfolio diversification. MedTech’s growth was supported by contributions from recent acquisitions and new product introductions, offsetting short-term headwinds in orthopedics and procedure volumes.
Looking ahead, management identified 2025 as a catalyst year, focusing on expanding key brands, advancing the pipeline, and executing on recently closed acquisitions. The company reaffirmed its full-year adjusted earnings guidance, while CFO Joe Wolk said the updated revenue outlook incorporates the addition of Caplyta from the IntraCellular acquisition. Management flagged the importance of mitigating new tariffs, navigating the loss of exclusivity for major products, and sustaining growth from its expanding medicine pipeline.
Key Insights from Management’s Remarks
Johnson & Johnson’s management attributed the quarter’s outperformance to both resilience in innovative medicine and robust execution in MedTech. Their remarks underscored the effects of biosimilar competition, new product launches, and strategic investments:
-
STELARA biosimilar headwinds managed: Despite anticipated declines from biosimilar competition and U.S. Medicare Part D redesign, management emphasized that operational sales growth in innovative medicine was driven by double-digit expansion in eleven core brands, with Tremfya and DARZALEX noted for strong demand.
-
Key launches in immunology and oncology: Tremfya’s new indications in inflammatory bowel disease and Crohn’s disease accelerated growth. Meanwhile, expanded European approval and new data for DARZALEX and riboflavin plus LASCRUZ in oncology highlighted the pipeline’s contribution to sales.
-
MedTech growth from acquisitions and new products: The acquisitions of Abiomed and Shockwave were cited as meeting expectations and broadening the MedTech portfolio. Newly launched devices, such as the Javelin Peripheral IVL catheter and expanded robotic surgery trials, contributed to segment growth.
-
Operational and margin pressures addressed: Management discussed cost pressures from product mix, tariffs, and acquisition-related expenses, but pointed to spending discipline and a restructuring program in surgery as measures to improve profitability by 2027.
-
Capital allocation and investment priorities: The company reiterated its commitment to R&D, announcing plans to invest over $55 billion in U.S. manufacturing and technology over four years, alongside a dividend increase for the sixty-third consecutive year.
Drivers of Future Performance
Management’s outlook for 2025 anticipates operational sales growth between 3.3% and 4.3% (midpoint $92 billion) and maintains adjusted earnings per share guidance at a midpoint of $10.60, as the company integrates new assets and navigates market headwinds.
-
Pipeline and new indications: The expansion of Tremfya, Caplyta, and upcoming filings for Ichotrochindra in autoimmune diseases are expected to offset the impact of lost exclusivity in other key products, supporting revenue growth.
-
Tariffs and margin management: Newly imposed tariffs, particularly affecting MedTech exports to China, present a $400 million headwind; management is pursuing production shifts and advocating for favorable tax policies to mitigate this impact.
-
MedTech portfolio optimization: Restructuring and exiting non-strategic product lines, combined with investment in higher-growth devices, are expected to support longer-term margin improvement and segment growth.
Top Analyst Questions
- Larry Biegelsen (Wells Fargo): Asked about the $400 million tariff impact and mitigation strategies; management said tariffs primarily hit MedTech exports to China and are seeking production adjustments rather than price increases.
- Chris Schott (JPMorgan): Inquired about gross margin drivers; CFO Joe Wolk cited product mix, STELARA’s decline, and currency headwinds, and noted that consensus estimates were likely too optimistic.
- Asad Hader (Goldman Sachs): Requested quantitative detail on STELARA biosimilar erosion; management reiterated guidance based on the HUMIRA precedent and emphasized offsetting growth in other brands.
- Joanne Wuensch (Citibank): Questioned the orthopedics segment’s underperformance and recovery timeline; management acknowledged competitive pressures and expected innovation and new launches to drive improvement.
- Matt Miksic (Barclays): Sought clarity on immunology opportunities, especially for Tremfya and Ichotrochindra; executives highlighted strong initial launches and market expansion potential for both products.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will be monitoring (1) the rollout and uptake of new indications for Tremfya and Caplyta, (2) the pace of MedTech’s margin improvement and execution of the surgery restructuring plan, and (3) progress on upcoming regulatory submissions and product launches, especially for Ichotrochindra in autoimmune diseases. The handling of tariffs and biosimilar competition will also be key themes to watch.
Should you be optimistic or skeptical about JNJ's ability to win? See for yourself in our free research report.
The Best Stocks for High-Quality Investors
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today.
